閉経後膣萎縮症：市場洞察・疫学・市場予測 (～2034年)

当レポートでは、世界の主要7カ国における閉経後膣萎縮症の市場を調査し、疾患の背景・概要、疫学、治療と管理の概要、市場促進要因と障壁、アンメットニーズ、上市薬およびパイプライン薬のプロファイル、主要国の市場規模の推移・予測、競合情勢などをまとめ、最良の機会を発掘し、市場の潜在力を評価します。

対象地域

• 米国
• 欧州5カ国（ドイツ・フランス・イタリア・スペイン・英国）
• 日本

調査期間：2020年～2034年

レポートハイライト

• 閉経後膣萎縮症の市場は、疾患に対する認識の高まりと、医療支出の世界的増加により、今後数年間で変化を示すと考えられています。
• 企業や研究機関は、閉経後膣萎縮症の研究開発に影響を与える可能性のある課題を分析し、その機会を探るべく取り組んでいます。開発中の治療薬は、病態を治療/改善するための新規アプローチに焦点を当てています。
• 大手企業は閉経後膣萎縮症の治療薬の開発に取り組んでいます。新たな治療薬の上市は市場に大きな影響を与える見通しです。
• 閉経後膣萎縮症の新規治療薬の開発には、疾患病態のより深い理解が必要です。
• 当社の開発段階ごと（第III相および第II相）のパイプラインアセットに関する詳細な分析、さまざまな新興動向、詳細な臨床プロファイル、主なクロスコンペティション、発売日、製品開発活動を含むパイプライン薬の比較分析は、研究開発活動の全体的なシナリオを特定することで、治療ポートフォリオに関する意思決定プロセスにおいてクライアントを支援します。

目次

第1章 重要な洞察

第2章 閉経後膣萎縮症：エグゼクティブサマリー

第3章 閉経後膣萎縮症：競合情報分析

第4章 閉経後膣萎縮症：市場概要

• 総市場のシェア (％) の分布：2020年
• 総市場のシェア (％) の分布：2034年

第5章 閉経後膣萎縮症：疾患の背景・概要

• 兆候と症状
• 病態生理
• リスク因子
• 診断

第6章 ペイシェントジャーニー

第7章 閉経後膣萎縮症：疫学・患者人口

• 疫学：主要調査結果
• 前提・根拠：主要7カ国
• 疫学シナリオ：主要7カ国
  • 主要7カ国における閉経後膣萎縮症の疫学シナリオ：2020-2034年
• 疫学：米国
• 疫学：欧州5カ国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 疫学：日本

第8章 治療アルゴリズム・現在の治療・医療行為

• 閉経後膣萎縮症の治療と管理
• 閉経後膣萎縮症の治療アルゴリズム

第9章 アンメットニーズ

第10章 閉経後膣萎縮症治療の主なエンドポイント

第11章 上市済み製品

• 主要7カ国の上市製品リスト
• 医薬品名・企業名
  • 製品説明
  • 規制のマイルストーン
  • その他の開発活動
  • 重要臨床試験
  • 主要臨床試験の概要

第12章 新たな治療法

• 主なクロスコンペティション
• 医薬品名・企業名
  • 製品説明
  • その他の開発活動
  • 臨床開発
  • 安全性と有効性
  • 製品プロファイル

第13章 閉経後膣萎縮症：主要7カ国市場の分析

• 主要調査結果
• 主要7カ国の市場規模
• 主要7カ国の市場規模：治療薬別

第14章 属性分析

第15章 主要7カ国：市場の展望

• 米国：市場規模
• 欧州5カ国：市場規模・展望
• ドイツ
• フランス
• イタリア
• スペイン
• 英国
• 日本市場の展望

第16章 閉経後膣萎縮症：アクセスと償還の概要

第17章 KOLの見解

第18章 市場促進要因

第19章 市場の障壁

第20章 付録

第21章 DelveInsightの能力

第22章 免責事項

第23章 DelveInsightについて

List of Tables

• Table 1: 7MM Postmenopausal Vaginal Atrophy Epidemiology (2020-2034)
• Table 2: 7MM Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases (2020-2034)
• Table 3: Postmenopausal Vaginal Atrophy Epidemiology in the United States (2020-2034)
• Table 4: Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases in the United States (2020-2034)
• Table 5: Postmenopausal Vaginal Atrophy Epidemiology in Germany (2020-2034)
• Table 6: Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases in Germany (2020-2034)
• Table 7: Postmenopausal Vaginal Atrophy Epidemiology in France (2020-2034)
• Table 8: Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases in France (2020-2034)
• Table 9: Postmenopausal Vaginal Atrophy Epidemiology in Italy (2020-2034)
• Table 10: Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases in Italy (2020-2034)
• Table 11: Postmenopausal Vaginal Atrophy Epidemiology in Spain (2020-2034)
• Table 12: Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases in Spain (2020-2034)
• Table 13: Postmenopausal Vaginal Atrophy Epidemiology in the UK (2020-2034)
• Table 14: Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases in the UK (2020-2034)
• Table 15: Postmenopausal Vaginal Atrophy Epidemiology in Japan (2020-2034)
• Table 16: Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases in Japan (2020-2034)
• Table 17: Drug Name, Clinical Trials by Recruitment status
• Table 18: Drug Name, Clinical Trials by Zone
• Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Table 20: Region-wise Market Size in USD, Million (2020-2034)
• Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Table 22: United States Market Size in USD, Million (2020-2034)
• Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Table 24: Germany Market Size in USD, Million (2020-2034)
• Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Table 26: France Market Size in USD, Million (2020-2034)
• Table 27: France Market Size by Therapy in USD, Million (2020-2034)
• Table 28: Italy Market Size in USD, Million (2020-2034)
• Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Table 30: Spain Market Size in USD, Million (2020-2034)
• Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Table 32: United Kingdom Market Size in USD, Million (2020-2034)
• Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Table 34: Japan Market Size in USD, Million (2020-2034)
• Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

• Figure 1: 7MM Postmenopausal Vaginal Atrophy Epidemiology (2020-2034)
• Figure 2: 7MM Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases (2020-2034)
• Figure 3: Postmenopausal Vaginal Atrophy Epidemiology in the United States (2020-2034)
• Figure 4: Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases in the United States (2020-2034)
• Figure 5: Postmenopausal Vaginal Atrophy Epidemiology in Germany (2020-2034)
• Figure 6: Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases in Germany (2020-2034)
• Figure 7: Postmenopausal Vaginal Atrophy Epidemiology in France (2020-2034)
• Figure 8: Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases in France (2020-2034)
• Figure 9: Postmenopausal Vaginal Atrophy Epidemiology in Italy (2020-2034)
• Figure 10: Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases in Italy (2020-2034)
• Figure 11: Postmenopausal Vaginal Atrophy Epidemiology in Spain (2020-2034)
• Figure 12: Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases in Spain (2020-2034)
• Figure 13: Postmenopausal Vaginal Atrophy Epidemiology in the UK (2020-2034)
• Figure 14: Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases in the UK (2020-2034)
• Figure 15: Postmenopausal Vaginal Atrophy Epidemiology in Japan (2020-2034)
• Figure 16: Postmenopausal Vaginal Atrophy Diagnosed and Treatable Cases in Japan (2020-2034)
• Figure 17: Drug Name, Clinical Trials by Recruitment status
• Figure 18: Drug Name, Clinical Trials by Zone
• Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Figure 20: Region-wise Market Size in USD, Million (2020-2034)
• Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Figure 22: United States Market Size in USD, Million (2020-2034)
• Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Figure 24: Germany Market Size in USD, Million (2020-2034)
• Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Figure 26: France Market Size in USD, Million (2020-2034)
• Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
• Figure 28: Italy Market Size in USD, Million (2020-2034)
• Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Figure 30: Spain Market Size in USD, Million (2020-2034)
• Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
• Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Figure 34: Japan Market Size in USD, Million (2020-2034)
• Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary

DelveInsight's "Postmenopausal Vaginal Atrophy - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Postmenopausal Vaginal Atrophy, historical and forecasted epidemiology as well as the Postmenopausal Vaginal Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Postmenopausal Vaginal Atrophy market report provides current treatment practices, emerging drugs, Postmenopausal Vaginal Atrophy market share of the individual therapies, current and forecasted Postmenopausal Vaginal Atrophy market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Postmenopausal Vaginal Atrophy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Postmenopausal Vaginal Atrophy Disease Understanding and Treatment Algorithm

The DelveInsight Postmenopausal Vaginal Atrophy market report gives a thorough understanding of the Postmenopausal Vaginal Atrophy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Postmenopausal Vaginal Atrophy.

Treatment

It covers the details of conventional and current medical therapies available in the Postmenopausal Vaginal Atrophy market for the treatment of the condition. It also provides Postmenopausal Vaginal Atrophy treatment algorithms and guidelines in the United States, Europe, and Japan.

Postmenopausal Vaginal Atrophy Epidemiology

The Postmenopausal Vaginal Atrophy epidemiology division provide insights about historical and current Postmenopausal Vaginal Atrophy patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Postmenopausal Vaginal Atrophy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Postmenopausal Vaginal Atrophy Epidemiology

The epidemiology segment also provides the Postmenopausal Vaginal Atrophy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Postmenopausal Vaginal Atrophy Drug Chapters

Drug chapter segment of the Postmenopausal Vaginal Atrophy report encloses the detailed analysis of Postmenopausal Vaginal Atrophy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Postmenopausal Vaginal Atrophy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Postmenopausal Vaginal Atrophy treatment.

Postmenopausal Vaginal Atrophy Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Postmenopausal Vaginal Atrophy treatment.

Postmenopausal Vaginal Atrophy Market Outlook

The Postmenopausal Vaginal Atrophy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Postmenopausal Vaginal Atrophy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Postmenopausal Vaginal Atrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Postmenopausal Vaginal Atrophy market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Postmenopausal Vaginal Atrophy market in 7MM.

The United States Market Outlook

This section provides the total Postmenopausal Vaginal Atrophy market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Postmenopausal Vaginal Atrophy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Postmenopausal Vaginal Atrophy market size and market size by therapies in Japan is also mentioned.

Postmenopausal Vaginal Atrophy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Postmenopausal Vaginal Atrophy market or expected to get launched in the market during the study period 2020-2034. The analysis covers Postmenopausal Vaginal Atrophy market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Postmenopausal Vaginal Atrophy Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Postmenopausal Vaginal Atrophy key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Postmenopausal Vaginal Atrophy emerging therapies.

Reimbursement Scenario in Postmenopausal Vaginal Atrophy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Postmenopausal Vaginal Atrophy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Postmenopausal Vaginal Atrophy market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Postmenopausal Vaginal Atrophy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Postmenopausal Vaginal Atrophy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Postmenopausal Vaginal Atrophy epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Postmenopausal Vaginal Atrophy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Postmenopausal Vaginal Atrophy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Postmenopausal Vaginal Atrophy market

Report Highlights:

• In the coming years, Postmenopausal Vaginal Atrophy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Postmenopausal Vaginal Atrophy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Postmenopausal Vaginal Atrophy. Launch of emerging therapies will significantly impact the Postmenopausal Vaginal Atrophy market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Postmenopausal Vaginal Atrophy
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Postmenopausal Vaginal Atrophy Report Insights

• Patient Population
• Therapeutic Approaches
• Postmenopausal Vaginal Atrophy Pipeline Analysis
• Postmenopausal Vaginal Atrophy Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Postmenopausal Vaginal Atrophy Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Postmenopausal Vaginal Atrophy Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Postmenopausal Vaginal Atrophy Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Postmenopausal Vaginal Atrophy market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Postmenopausal Vaginal Atrophy total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Postmenopausal Vaginal Atrophy market size during the forecast period (2024-2034)?
• At what CAGR, the Postmenopausal Vaginal Atrophy market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Postmenopausal Vaginal Atrophy market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Postmenopausal Vaginal Atrophy market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Postmenopausal Vaginal Atrophy?
• What is the historical Postmenopausal Vaginal Atrophy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Postmenopausal Vaginal Atrophy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Postmenopausal Vaginal Atrophy?
• Out of all 7MM countries, which country would have the highest prevalent population of Postmenopausal Vaginal Atrophy during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Postmenopausal Vaginal Atrophy treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Postmenopausal Vaginal Atrophy in the USA, Europe, and Japan?
• What are the Postmenopausal Vaginal Atrophy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Postmenopausal Vaginal Atrophy?
• How many therapies are developed by each company for Postmenopausal Vaginal Atrophy treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Postmenopausal Vaginal Atrophy treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Postmenopausal Vaginal Atrophy therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Postmenopausal Vaginal Atrophy and their status?
• What are the key designations that have been granted for the emerging therapies for Postmenopausal Vaginal Atrophy?
• What are the global historical and forecasted market of Postmenopausal Vaginal Atrophy?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Postmenopausal Vaginal Atrophy market
• To understand the future market competition in the Postmenopausal Vaginal Atrophy market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Postmenopausal Vaginal Atrophy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Postmenopausal Vaginal Atrophy market
• To understand the future market competition in the Postmenopausal Vaginal Atrophy market

Table of Contents

1. Key Insights

2. Executive Summary of Postmenopausal Vaginal Atrophy

3. Competitive Intelligence Analysis for Postmenopausal Vaginal Atrophy

4. Postmenopausal Vaginal Atrophy: Market Overview at a Glance

• 4.1. Postmenopausal Vaginal Atrophy Total Market Share (%) Distribution in 2020
• 4.2. Postmenopausal Vaginal Atrophy Total Market Share (%) Distribution in 2034

5. Postmenopausal Vaginal Atrophy: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Postmenopausal Vaginal Atrophy Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Postmenopausal Vaginal Atrophy Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Postmenopausal Vaginal Atrophy Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Postmenopausal Vaginal Atrophy Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Postmenopausal Vaginal Atrophy Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Postmenopausal Vaginal Atrophy Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Postmenopausal Vaginal Atrophy Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Postmenopausal Vaginal Atrophy Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Postmenopausal Vaginal Atrophy Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Postmenopausal Vaginal Atrophy Treatment and Management
• 8.2. Postmenopausal Vaginal Atrophy Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Postmenopausal Vaginal Atrophy Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Postmenopausal Vaginal Atrophy: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Postmenopausal Vaginal Atrophy Market Size in 7MM
• 13.3. Postmenopausal Vaginal Atrophy Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Postmenopausal Vaginal Atrophy Total Market Size in the United States
  • 15.1.2. Postmenopausal Vaginal Atrophy Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Postmenopausal Vaginal Atrophy Total Market Size in Germany
  • 15.3.2. Postmenopausal Vaginal Atrophy Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Postmenopausal Vaginal Atrophy Total Market Size in France
  • 15.4.2. Postmenopausal Vaginal Atrophy Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Postmenopausal Vaginal Atrophy Total Market Size in Italy
  • 15.5.2. Postmenopausal Vaginal Atrophy Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Postmenopausal Vaginal Atrophy Total Market Size in Spain
  • 15.6.2. Postmenopausal Vaginal Atrophy Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Postmenopausal Vaginal Atrophy Total Market Size in the United Kingdom
  • 15.7.2. Postmenopausal Vaginal Atrophy Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Postmenopausal Vaginal Atrophy Total Market Size in Japan
  • 15.8.3. Postmenopausal Vaginal Atrophy Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Postmenopausal Vaginal Atrophy

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.